一二三
Lv1
90 积分
2021-03-26 加入
-
Statins and thyroid eye disease (TED): a systematic review
26天前
已完结
-
亚洲人群的甲状腺眼病状况及其诊治进展
26天前
已完结
-
Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
2个月前
已完结
-
甲状腺相关性眼病的指南2022年
2个月前
已完结
-
[Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]
3个月前
已完结
-
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
3个月前
已完结
-
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
3个月前
已完结
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
3个月前
已完结
-
SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection
5个月前
已完结
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
5个月前
已完结